# ASP Isotopes Inc. (ASPI) — merger/definitive [completed] Source: SEC API (secapi.ai) · situation sit_2094d79ca748419f42fe · retrieved 2026-08-11T15:53:22.401Z ## Overview ASP Isotopes is developing a differentiated isotope enrichment platform using its proprietary Aerodynamic Separation Process (ASP technology) and Quantum Enrichment (QE technology) to produce isotopes for nuclear medicine, next-generation semiconductors, and nuclear energy applications. ASP Isotopes Inc. announced a proposed merger involving ENDRA Life Sciences Inc., with ASP Isotopes' subsidiaries Renergen and Noble Africa (holding company for Renergen) as parties to the transaction. ENDRA intends to file a registration statement on Form S-4 containing a proxy statement and prospectus with the SEC in connection with the proposed transactions. The filing does not disclose a transaction value, consideration type, expected close date, or other specific deal terms at this stage. ## Terms - Counterparty: ENDRA Life Sciences Inc. · Deal value: $50.0M · Consideration: cash · Stake: 89% ## Key dates - Announced 2026-07-22 · Expected close 2026-12-31 · Completed 2026-07-22 ## Timeline - 2026-07-22 · 425 (0001477932-26-004434): 425 - ASP Isotopes Inc. — *ENDRA Life Sciences Inc. is an electromedical and electrotherapeutic apparatus company (SIC 3845) based in Ann Arbor, Michigan.* ASP Isotopes Inc. and its subsidiaries Renergen Limited and Noble Africa LLC have proposed a merger with ENDRA Life Sciences Inc. (the "Proposed Transactions"). The transaction involves Renergen, a wholly owned subsidiary of ASP Isotopes that operates the Virginia Gas Project in South Africa, combining with ENDRA. Following the closing of the Proposed Transactions, the combined company is expected to list on the Nasdaq exchange. The transaction is subject to approval by ENDRA stockholders and satisfaction of customary closing conditions, including obtaining required governmental approvals and completion of proposed debt financing from the U.S. Development Finance Corporation ($500 million facility) and Standard Bank SA ($250 million facility) for Phase 2 of the Virginia Gas Project. https://www.sec.gov/Archives/edgar/data/1921865/0001477932-26-004434.txt - 2026-07-22 · 425 (0001477932-26-004439): 425 - ASP Isotopes Inc. — *ASP Isotopes Inc. is a holding company that owns Renergen Limited, a South African helium and liquefied natural gas producer with a world-class helium reserve containing approximately 3% helium concentration and planned Phase 1 production of 70 Mcf per day of helium and 2,500 gigajoules per day of LNG.* ASP Isotopes Inc. (ASPI) announced a proposed merger of its wholly owned subsidiary Noble Africa LLC (which holds Renergen Limited) with ENDRA Life Sciences Inc. (ticker NDRA). Upon completion, ASPI will own approximately 89% of the combined entity, with the current ENDRA public float and a concurrent PIPE investment comprising approximately 11% ownership. The combined company will be called Noble Africa and will focus on Renergen's helium and liquefied natural gas operations in South Africa. ASPI expects to file a Form S-4 with the SEC in early August 2026, with shareholder votes from both ASPI and ENDRA required before closing, anticipated in Q4 2026. https://www.sec.gov/Archives/edgar/data/1921865/0001477932-26-004439.txt - 2026-08-04 · 425 (0001193125-26-333141): 425 - ASP Isotopes Inc. — *ASP Isotopes Inc. is an advanced materials company developing isotope enrichment technologies for critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy, with operations including the Renergen helium and LNG production subsidiary in South Africa.* ASP Isotopes Inc. announced a planned reverse merger between its subsidiary Noble Africa LLC and ENDRA Life Sciences Inc. (Nasdaq: NDRA), with the combined company expected to be renamed Noble Africa Inc. and listed on Nasdaq under ticker "NOBA". In connection with the merger, ASP Isotopes secured commitments for a private placement of approximately $50 million gross proceeds, including approximately $20 million from ASP Isotopes as lead investor and approximately $30 million from other investors, including $750,000 from certain directors and management of ASP Isotopes. Following the transactions, ASP Isotopes will own approximately 89% of Noble Africa with a free float of approximately 11%. The transactions are expected to close during 2H 2026, subject to customary closing conditions. https://www.sec.gov/Archives/edgar/data/1921865/0001193125-26-333141.txt - 2026-08-05 · 425 (0001193125-26-335463): 425 - ASP Isotopes Inc. — *ASP Isotopes is developing a differentiated isotope enrichment platform using its proprietary Aerodynamic Separation Process (ASP technology) and Quantum Enrichment (QE technology) to produce isotopes for nuclear medicine, next-generation semiconductors, and nuclear energy applications.* ASP Isotopes Inc. announced a proposed merger involving ENDRA Life Sciences Inc., with ASP Isotopes' subsidiaries Renergen and Noble Africa (holding company for Renergen) as parties to the transaction. ENDRA intends to file a registration statement on Form S-4 containing a proxy statement and prospectus with the SEC in connection with the proposed transactions. The filing does not disclose a transaction value, consideration type, expected close date, or other specific deal terms at this stage. https://www.sec.gov/Archives/edgar/data/1921865/0001193125-26-335463.txt ## Citations - 0001477932-26-004434 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000147793226004434 - 0001477932-26-004439 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000147793226004439 - 0001193125-26-333141 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526333141 - 0001193125-26-335463 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526335463